$36.8m raise, page-24

The drug is for a disease with no effective SOC. Previous results suggest it works and has good safety. These are two things competitors cant say.

Both the EMA and FDA have awarded ODD for this drug for this disease. FDA have also awarded an PRV.

I cant see where the doom feelings are coming from. Approval for the EMA trial, and having finance to see that trial through has just added a lot of value to ANP. Fast track approval ontop will send its value even higher, and as this disease has an unmet need, fast track approval has a good chance.

The PRV if used, eases and quickens the approval process, while greatly reduced costs.

ANP is now the most derisked it has ever been. And there is a muti-pathway pipeline available from the one drug into different indications.

A great start to the weekend.